(Q36839768)

16 August 2017

1 reference

title

Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors (English)

1 reference

16 August 2017

1

Rafael Rosell

1 reference

16 August 2017

Miquel Taron

2

1 reference

16 August 2017

Jose Javier Sanchez

series ordinal

3

1 reference

16 August 2017

Luis Paz-Ares

series ordinal

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

16 August 2017

1 reference

16 August 2017

3

1 reference

16 August 2017

3

1 reference

16 August 2017

277-283

1 reference

ERBB receptors and cancer: the complexity of targeted inhibitors

16 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Biological and clinical implications of EGFR mutations in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

From the bench to the bed: individualizing treatment in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.277

21 January 2018

Identifiers

DOI

10.2217/14796694.3.3.277

1 reference

16 August 2017

1 reference